New CPIC Guideline: CYP2D6 and atomoxetine

The CPIC Guideline for atomoxetine and CYP2D6 is now published in Clinical Pharmacology and Therapeutics. The accepted article can be viewed on the PharmGKB page for atomoxetine, and the CPIC website.

Atomoxetine is a non-stimulant medication used in the treatment of attention-deficit/hyperactivity disorder. Atomoxetine is metabolized by CYP2D6 and  genetic variation effects atomoxetine pharmacokinetics. Atomoxetine exposure is on average 10-fold higher in CYP2D6 poor metabolizers (PMs) compared to non-PMs and the likelihood of favorable treatment response and side effects are both reported to be higher in CYP2D6 PMs compared to non-PMs.

The CPIC guideline and supplement summarize evidence from the literature and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype. The therapeutic recommendation for each CYP2D6 phenotype class also includes guidance for plasma drug concentration testing.

For further details see the guidelines and supplement on CPIC, or on the pages for atomoxetine on PharmGKB.